Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

Molecular Cancer Therapeutics

Volumn 11, Issue 12, 2012, Pages 2674-2684

  Gleason, Michelle K ^a   Verneris, Michael R ^a   Todhunter, Deborah A ^a   Zhang, Bin ^a   McCullar, Valarie ^a   Zhou, Sophia X ^a   Panoskaltsis Mortari, Angela ^a   Weiner, Louis M ^b   Vallera, Daniel A ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CD16 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING CELL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BISPECIFIC KILLER CELL ENGAGER; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KILLER CELL; MAST CELL DEGRANULATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAJI CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRISPECIFIC KILLER CELL ENGAGER;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; BURKITT LYMPHOMA; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, IGG; SIGNAL TRANSDUCTION;

EID: 84871389574     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0692     Document Type: Article

References (46)

1. American Cancer Society. Cancer facts & figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Armitage JO, Weisenburger DD. New approach to classifying non- Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95. (Pubitemid 28363044)
3. Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs 2011;25:55-61.
4. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33.
5. Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, et al. Effective lysis of lymphoma cells with a stabilised bispecific singlechain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 2005;130:218-28. (Pubitemid 41602522)
6. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999;36:433-45. (Pubitemid 29336224)
7. Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011;303:128-39.
8. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40. (Pubitemid 33043908)
9. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91. (Pubitemid 44707903)
10. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74. (Pubitemid 40563170)
11. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19: 197- 223.
12. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159- 66.
13. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004;306:1517- 9.
14. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/ lymphoma. Clin Cancer Res 2005;11:3879-88. (Pubitemid 40685609)
15. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012;119:3064-72.
16. Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011;118: 4053- 61.
17. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-62.
18. Trotta R, Puorro KA, Paroli M, Azzoni L, Abebe B, Eisenlohr LC, et al. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol 1998;161:6648-56. (Pubitemid 28562206)
19. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15-22. (Pubitemid 39626587)
20. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009;254:149-54.
21. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-45. (Pubitemid 46356962)
22. Huntington ND, Xu Y, Nutt SL, Tarlinton DM. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med 2005;201:1421-33. (Pubitemid 40664086)
23. Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc Natl Acad Sci U S A 2006;103:7012-7.
24. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, et al. A novel CD19-directed recombinant bispecifi c antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008;31:871-84.
25. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010;115:2167-76.
26. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004;173:3653-9. (Pubitemid 39280725)
27. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005;202:1001-12. (Pubitemid 41396899)
28. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non- Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-43. (Pubitemid 40516580)
29. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Crosslinking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998;160:1565-72. (Pubitemid 28106439)
30. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13: 47-57.
31. Fujimoto M, Poe JC, Hasegawa M, Tedder TF. CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol Res 2000;22: 281-98. (Pubitemid 32382241)
32. Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF. CD19 ampli fies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol 1999;162:7088-94. (Pubitemid 29277677)
33. Roifman CM, Ke S. CD19 is a substrate of the antigen receptorassociated protein tyrosine kinase in human B cells. Biochem Biophys Res Commun 1993;194:222- 5.
34. Assarsson E, Kambayashi T, Persson CM, Chambers BJ, Ljunggren HG. 2B4/CD48-mediated regulation of lymphocyte activation and function. J Immunol 2005;175:2045-9. (Pubitemid 41113807)
35. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 1992;149:1115- 23.
36. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28:57-78.
37. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells. J Immunol 2002;169:3676-85.
38. Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol 2011;8:281-4.
39. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of Blymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 1999;11:191-200. (Pubitemid 29428812)
40. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90. (Pubitemid 32368037)
41. Schultze JL, Michalak S, Lowne J, Wong A, Gilleece MH, Gribben JG, et al.Human non-germinal center Bcell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med 1999;189:1-12.
42. Sartori A, Ma X, Gri G, Showe L, Benjamin D, Trinchieri G. Interleukin- 12: an immunoregulatory cytokine produced by B cells and antigenpresenting cells. Methods 1997;11:116-27. (Pubitemid 27207923)
43. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983- 92.
44. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100. (Pubitemid 34229476)
45. Suzuki T, Coustan-Smith E, Mihara K, Campana D. Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. Leukemia 2002;16:1276-84.
46. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087- 93.